239PBaseline sum of longest diameter in target lesions by response evaluation criteria in solid tumor as a prognostic factor in patients with advanced hepatocellylar carcinoma receiving sorafenib treatment

Background: Sorafenib has been established as a standard treatment for advanced hepatocellular carcinoma (HCC) for 10 years, however, prognostic factors for patients with advanced HCC receiving sorafenib treatment are presently not well established. Recently, tumor volume represented by Baseline Sum of Longest Diameter (BSLD) of target lesions has been reported as a prognostic factor in some malignancies. The objective of this study was to clarify the prognostic impact of BSLD by Response Evaluation Criteria in Solid Tumor (RECIST) in patients with advanced HCC receiving sorafenib treatment. Methods: We analyzed 232 consecutive patients with advanced HCC who had received sorafenib treatment as first-linechemotherapy from June 2009 to December 2014. Prognostic factors, including the baseline sum longest diameter (BSLD) by RECIST ver1.1 were evaluated by multivariable analysis. Results: Of patients treated with sorafenib (male, 78%; median age, 68 years), 72% had Child-Pugh A and 28% had Child-Pugh B. The median BSLD was 59 mm (range, 10-294). Median time to progression was 3.2 months, and median overall survival (OS) was 9.5 months. By multivariate analysis, BSLD ≥ 60mm (HR 1.55, 95% CI 1.13–2.01, P = 0.02), as well as performance status 1 or 2 (HR 2.01, 95% CI 1.57–2.55, P = 0.01), Child-Pugh class B (HR 2.32, 95% CI 1.78–2.69, P = 0.01), AFP ≥ 400 ng/ml (HR 1.52, 95% CI 1.13–2.01, P = 0.03), and presence of major vascular invasion (HR 1.43, 95% CI 1.08–1.88, P = 0.03) were statistically significant independent predictors of poor prognosis. Median OS of patients with BSLDs ≥ 60 mm and < 60 mm were 5.7 months and 14.5 months, respectively (P = 0.02). Conclusions: BSLD of target lesions by RECIST representing tumor volume is an independent prognostic factor of patients with advanced HCC receiving sorafenib treatment. Legal entity responsible for the study: Chiba University Ethnical Commitee Funding: None Disclosure: T. Chiba: Research grant from Bayer Yakuhin. S. Ogasawara: Receives speaker bureau honoraria. N. Kato: Receives speakers bureau honoraria and research grant from Bayer Yakuhin. All other authors have declared no conflicts of interest.